Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged $MYL
If Hatch-Waxman cases are governed by TC Heartland, will that lead to “generic friendly” districts?

Mylan ($MYL) recently prevailed on a motion to dismiss for improper venue in a pending Hatch-Waxman case for the drug Eliquis®.  Mylan successfully argued that Delaware was an improper venue under the recently test for venue in patent cases enunciated by the Supreme Court in TC Heartland.  What are the implications of TC Heartland governing venue in all Hatch-Waxman cases?  Will it lead to “generic friendly” judicial districts?

Read More
Markman AdvisorsMylan, Bristol-Meyers Squibb, MYL, $MYL, $BYL, BYL, $BMY, BMY, TC Heartland, venue, Hatch-Waxman, generic, brand, generic drug, Federal Circuit, Eliquis, Zachary Silbersher, SilbersherComment
Roche prevails on two IPR challenges to Herceptin patents—does it matter?

We previously wrote about Roche’s encroaching biosimilars for Ritxuan®, Herceptin®, and Avastin®.  This week, Roche prevailed on two IPRs covering patents for Herceptin®, but lost a third IPR covering another patent for the same drug. What does this mean? 

Read More
Markman AdvisorsRoche, Rituxan, Herceptin, Avastin, Celltrion, Amgen, Samsung Bioepis, Mylan, $PFE, $AMGN, $MYL, BPCIA, Zachary Silbersher, Silbersher, biosimilar, patent, IPR, Inter Partes Review, aBLAComment